Treatment of experimental mouse bladder tumour by LPS-induced epithelial cell shedding

British Journal of Cancer

Volumn 74, Issue 4, 1996, Pages 603-605

  Nativ, O ^a   Medalia, O ^b   Mor, Y ^c   Shajrawi, I ^a   Sabo, E ^a   Aronson, M ^b  

^a BNAI ZION MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Bladder neoplasm; Desquamation; Lipopolysaccharide; Shedding

Indexed keywords

ENDOTOXIN; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER EPITHELIUM; BLADDER TUMOR; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 0029763274     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.408     Document Type: Article

References (17)

1. ARONSON M, MEDALIA O, AMICHAY D AND NATIV O. (1988). Endotoxin-induced shedding of viable uroepithelial cells is an antimicrobial defence mechanism. Infect. Immun., 56, 1615-1617.
2. DING A, SANCHEZ E, TANCINCO M AND NATHAN C. (1992). Interactions of bacterial lipopolysaccharide with microtubule proteins. J. Immunol., 148, 2853-2858.
3. GARNICK MB, SCHADEF D AND ISRAEL M. (1984). Intravesical doxorubicin for prophylaxis in the management of recurrent superficial bladder carcinoma. J. Urol., 131, 43-46.
4. HERR WH, LAUDONE VP AND WHITMORE WF Jr. (1987). An overview of intravesical therapy for superficial bladder tumors. J. Urol., 138, 1363-1368.
5. HERR WH, BADALAMENT RA, AMATO DA, LAUDONE VP, FAIR WR AND WHITMORE WF Jr. (1989). Superficial bladder cancer treated with Bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J. Urol., 141, 22-28.
6. HULAND H, KLOPPEL G AND FEDDERSON I. (1990). Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma. Final evaluation of prospective multicenter study with 419 patients. J. Urol., 144, 68-71.
7. KAMAT MR, KULKARNI JN, TONGAOKNAR HB AND DALAL AF. (1994). Intravesical Bacillus Calmette-Guerin for superficial bladder cancer: experience with Danish 1331 strain. J. Urol., 152, 1424-1428.
8. KOONTZ WW Jr, PROUT GR AND SMITH W. (1981). The use of intravesical thiotepa in the management of noninvasive carcinoma of the bladder. J. Urol., 125, 307-312.
9. LAMM DL AND GRIFFITH JE. (1992). Intravesical therapy: Does it affect the natural history of superficial bladder cancer. Semin. Urol., 10, 39-43.
10. NATIV O, MEDALIA O, ENGELBERG SI, RAVIV G AND ARONSON M. (1994). Enhanced cytologic detection of early stage mouse bladder tumor following induction of uroepithelial cell shedding. J. Urol., 152, 217-219.
11. RUBBEN H, LUTZEYER LW, FISCHER N, DEUTZ F, LA GRANGE I AND GIANI G. (1988). Natural history and treatment of low and high risk superficial bladder tumors. J. Urol., 139, 283-285.
12. SCHULMAN CC, ROBINSON M AND DENIS L. (1982). Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, VM-26 and TUR alone. Eur. Urol., 8, 207-212.
13. SILVERBERG E, BORING C AND SQUIRES T. (1990). Cancer statistics-1990. Ca-Cancer J. Clin., 40, 9-26.
14. SOLOWAY MS, MURPHY WM AND DEFUSIA MD. (1981). The effect of mitomycin C on superficial bladder cancer. J. Urol., 125, 646-648.
15. SOLOWAY MS. (1987). Selecting initial therapy for bladder cancer. Cancer, 60, 502-513.
16. TAKAYAMA K, RIBI E AND CANTRELL JL. (1981). Isolation of a nontoxic lipid A fraction containing tumor regression activity. Cancer Res., 41, 2654-2657.
17. TORTI FM AND LUM BI. (1984). The biology and treatment of superficial bladder cancer. J. Clin. Oncol., 2, 505-551.